Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study
The Annals of Thoracic Surgery 97(1): 22-28
Article 2013 English
Authors
RB
Robert M.A. van der Boon
BM
Bertrand Marcheix
DT
Didier Tchetchè
Abstract
2 min read
Background
There are no direct comparisons between transapical aortic valve implantation (TA-AVI) and transfemoral aortic valve implantation (TF-AVI). Therefore, the aim of this study was to compare the short-term and midterm outcomes of TA-AVI versus TF-AVI.
Methods
Data from four European centers were pooled and analyzed. To minimize differences between TA-AVI and TF-AVI multivariable analysis was used. Study endpoints were defined according to the Valve Academic Research Consortium-I criteria at 30 days and 1 year. Primary endpoints of this study were 30-day all-cause mortality and mortality during follow-up.
Results
A total of 882 patients underwent TAVI, of whom 793 (89.9%) underwent TF-AVI and 89 (10.1%) underwent TA-AVI. Patients undergoing TA-AVI had a higher estimated risk of mortality as defined by the logistic European System for Cardiac Operative Risk Evaluation score (median 27.0, interquartile range [IQR]: 20.2 to 33.8 versus median 20.0, IQR: 12.3 to 27.7; p < 0.001) and The Society of Thoracic Surgeons Score (median 10.2, IQR: 5.3 to 9.9 versus median 6.7, IQR: 3.5 to 9.9; p < 0.001) and had more comorbidities. At 30 days, there was an increased risk of all-cause mortality in the TA-AVI group (odds ratio [OR] 3.12, 95% confidence interval [CI]: 1.43 to 6.82; p = 0.004). TF-AVI was associated with a higher frequency of major (OR 0.33, 95% CI: 0.12 to 0.90; p = 0.031) and minor vascular complications (OR 0.17, 95% CI: 0.04 to 0.71; p = 0.0015). In-hospital stay was significantly longer among patients undergoing TA-AVI (OR 2.29, 95% CI: 1.28 to 4.09; p = 0.05). During a median follow-up of 365 days (IQR: 174 to 557), TA-AVI was associated with an increased risk of all-cause mortality (hazard ratio 1.88, 95% CI: 1.23 to 2.87; p = 0.004).
Conclusions
In institutions performing a low volume of TA-AVI, the technique is associated with an increased risk of all-cause mortality and longer hospital stay but less vascular complications in comparison with TF-AVI. The interaction between experience and type of treatment on outcome requires further investigation before advocating one treatment over the other.
Nicolas M. Van Mieghem, Alaide Chieffo, Nicolas Dumonteil, Didier Tchetchè, Robert M.A. van der Boon, Gill Louise Buchanan, Bertrand Marcheix, Olivier Vahdat, Patrick W. Serruys, Jean Fajadet, Didier Carrié, Antonio Colombo, Peter P.T. de Jaegere
Alaide Chieffo, Gill Louise Buchanan, Nicolas M. Van Mieghem, Didier Tchetchè, Nicolas Dumonteil, Azeem Latib, Robert M.A. van der Boon, Olivier Vahdat, Bertrand Marcheix, Bruno Farah, Patrick W. Serruys, Jean Fajadet, Didier Carrié, Peter P.T. de Jaegere, Antonio Colombo
Nicolas M. Van Mieghem, Stuart J. Head, Wesley de Jong, Ron T. van Domburg, Patrick W. Serruys, Peter P. de Jaegere, Luc Jordaens, Johanna J.M. Takkenberg, Ad J.J.C. Bogers, A. Pieter Kappetein
Robert M.A. van der Boon, Rutger-Jan Nuis, Luis Benítez, Nicolas M. Van Mieghem, Sergio Pérez, Lidsa Cruz, Robert‐Jan van Geuns, Patrick W. Serruys, Ron T. van Domburg, Antonio Dager, Peter P.T. de Jaegere
Jeffrey J. Popma, David Adams, Michael J. Reardon, Steven J. Yakubov, Neal S. Kleiman, David Heimansohn, James Hermiller, G. Chad Hughes, J. Kevin Harrison, Joseph S. Coselli, José Gutiérrez Díez, Ali Kafi, Theodore Schreiber, Thomas G. Gleason, John V. Conte, Maurice Buchbinder, G. Michael Deeb, Blasé A. Carabello, Patrick W. Serruys, Sharla Chenoweth, Jae K. Oh
Discussion(0)
No comments yet. Be the first to comment.